ArticleScientific reports2025
Characterization of antibiotic resistance and biofilm formation in clinical Helicobacter pylori isolates from Ningxia, China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Tetracycline for Helicobacter pylori eradication: a narrative review from quadruple to dual therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Characterizing the profile transformation of Helicobacter pylori: increased secondary and multidrug resistance following failed eradication in Ningxia, China.BMC microbiology · 2026Article
- Comprehensive Pharmaceutical Care and Service-Related Outcomes During Vonoprazan-Amoxicillin Dual Therapy in Elderly Patients: A Retrospective Cohort Study.Patient preference and adherence · 2026Article
- Research Status and Prospects ofGastroenterology research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global issue of Helicobacter pylori (H. pylori) resistance has become increasingly severe, with biofilm formation identified as a significant contributor to drug resistance and subsequent treatment failures. This study investigated 78 strains of H. pylori in the Ningxia province of China over a two-year period, focusing on infection rates, drug resistance, biofilm formation, and genetic characteristics. The results indicated that 56 strains (71.8%) exhibited resistance, and 48 patients (61.5%) were diagnosed with atrophic gastritis. Notably, metronidazole resistance was the most prevalent, accounting for 65.3%, and multidrug-resistant strains were also identified. Further investigation revealed that high biofilm-forming H. pylori demonstrated a higher proportion of resistance to metronidazole, clarithromycin, and levofloxacin compared to low biofilm-forming H. pylori. Next-generation sequencing data demonstrated low homology among the strains, suggesting that this genetic diversity may drive the strains to evolve along distinct pathways, ultimately resulting in the emergence of more complex drug-resistant isolates within the studied population, despite the limited data size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.